Drug intelligence / Profile preview

pumecitinib

Development stage: Phase 3
Lead developer: PrimeGenX Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Pumecitinib is an oral small molecule inhibitor of Janus kinase 1 (JAK1). It is being developed for the treatment of autoimmune and inflammatory diseases, particularly rheumatoid arthritis. Pumecitinib selectively inhibits JAK1, a key enzyme involved in the signaling pathways of various pro-inflammatory cytokines implicated in immune-mediated diseases. By blocking JAK1 activity, pumecitinib reduces inflammation and modulates immune responses. The drug has been investigated primarily by South Korean pharmaceutical companies and has undergone clinical trials for rheumatoid arthritis.

Brand names: PG-011GelPG011GelPG 011Gel
Other names: pemetrexedinib gelPG-011 GelPG011 GelPG 011 Gel

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on pumecitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pumecitinib.

Explore the full profile